scispace - formally typeset
M

M. Paula Longhi

Researcher at Queen Mary University of London

Publications -  12
Citations -  1754

M. Paula Longhi is an academic researcher from Queen Mary University of London. The author has contributed to research in topics: Adipose tissue & Inflammation. The author has an hindex of 7, co-authored 11 publications receiving 1480 citations. Previous affiliations of M. Paula Longhi include Rockefeller University.

Papers
More filters
Journal ArticleDOI

Dendritic cells require a systemic type I interferon response to mature and induce CD4+ Th1 immunity with poly IC as adjuvant.

TL;DR: The adjuvant action of poly IC requires a widespread innate type I IFN response that directly links antigen presentation by DCs to adaptive immunity, which is required in both marrow–derived and radioresistant host cells for adaptive responses.
Journal ArticleDOI

Microbial stimulation fully differentiates monocytes to DC-SIGN/CD209+ dendritic cells for immune T cell areas

TL;DR: It is shown that fully differentiated monocyte-derived DCs (Mo-DCs) develop in mice and DC-SIGN/CD209a marks the cells, and the blood monocyte reservoir becomes the dominant presenting cell in response to select microbes, yielding DC- SIGN(+) cells with critical functions of DCs.
Journal ArticleDOI

Direct type I IFN but not MDA5/TLR3 activation of dendritic cells is required for maturation and metabolic shift to glycolysis after poly IC stimulation.

TL;DR: Type I IFN signaling is indispensable for the maturation of dendritic cells that are required to elicit an immune response, and it also controls a shift in cellular metabolism to meet the increased energy demands of DC maturation.
Journal ArticleDOI

Visceral Adipose Tissue Immune Homeostasis Is Regulated by the Crosstalk between Adipocytes and Dendritic Cell Subsets

TL;DR: It is reported that conventional dendritic cells in VAT acquire a tolerogenic phenotype through upregulation of pathways involved in adipocyte differentiation, promoting an anti-inflammatory milieu in vivo delaying the onset of obesity-induced chronic inflammation and insulin resistance.